Please Wait.....
Report
Ophthalmic Drugs Market (Disease Indication: Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, and Others; and Product Type: Prescription Drugs and OTC Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Market Report I 2022-10-11 I 243 Pages I Transparency Market Research
Ophthalmic Drugs Market - Scope of Report
TMR's report on the global ophthalmic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ophthalmic drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ophthalmic drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ophthalmic drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ophthalmic drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ophthalmic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ophthalmic drugs market.
The report delves into the competitive landscape of the global ophthalmic drugs market. Key players operating in the global ophthalmic drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ophthalmic drugs market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ophthalmic drugs.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover's
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team's expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Mergers & Acquisitions
5.5. COVID-19 Impact
6. Global Ophthalmic Drugs Market Analysis and Forecast, By Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast By Disease Indication, 2017-2031
6.3.1. Dry Eye
6.3.2. Glaucoma
6.3.3. Infection/Inflammation
6.3.4. Retinal Disorders
6.3.4.1. Wet AMD
6.3.4.2. Dry AMD
6.3.4.3. Diabetic Retinopathy
6.3.4.4. Others
6.3.5. Allergy
6.3.6. Uveitis
6.3.7. Others
6.4. Market Attractiveness By Disease Indication
7. Global Ophthalmic Drugs Market Analysis and Forecast, By Therapeutic Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast By Therapeutic Class, 2017-2031
7.3.1. Anti-inflammatory Drugs
7.3.1.1. NSAIDs
7.3.1.2. Steroids
7.3.2. Anti-infective Drugs
7.3.2.1. Anti-fungal Drugs
7.3.2.2. Anti-bacterial Drugs
7.3.2.3. Others
7.3.3. Anti-glaucoma Drugs
7.3.3.1. Alpha Agonist
7.3.3.2. Beta Blockers
7.3.3.3. Prostaglandin Analogs
7.3.3.4. Combined Medication
7.3.3.5. Others
7.3.4. Anti-allergy Drugs
7.3.5. Anti-VEGF Agents
7.3.6. Others
7.4. Market Attractiveness By Therapeutic Class
8. Global Ophthalmic Drugs Market Analysis and Forecast, By Product Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast By Product Type, 2017-2031
8.3.1. Prescription Drugs
8.3.2. OTC Drugs
8.4. Market Attractiveness By Product Type
9. Global Ophthalmic Drugs Market Analysis and Forecast, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast By Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Independent Pharmacies & Drug Stores
9.4. Market Attractiveness By Distribution Channel
10. Global Ophthalmic Drugs Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Ophthalmic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Disease Indication, 2017-2031
11.2.1. Dry Eye
11.2.2. Glaucoma
11.2.3. Infection/Inflammation
11.2.4. Retinal Disorders
11.2.4.1. Wet AMD
11.2.4.2. Dry AMD
11.2.4.3. Diabetic Retinopathy
11.2.4.4. Others
11.2.5. Allergy
11.2.6. Uveitis
11.2.7. Others
11.3. Market Value Forecast By Therapeutic Class, 2017-2031
11.3.1. Anti-inflammatory Drugs
11.3.1.1. NSAIDs
11.3.1.2. Steroids
11.3.2. Anti-infective Drugs
11.3.2.1. Anti-fungal Drugs
11.3.2.2. Anti-bacterial Drugs
11.3.2.3. Others
11.3.3. Anti-glaucoma Drugs
11.3.3.1. Alpha Agonist
11.3.3.2. Beta Blockers
11.3.3.3. Prostaglandin Analogs
11.3.3.4. Combined Medication
11.3.3.5. Others
11.3.4. Anti-allergy Drugs
11.3.5. Anti-VEGF Agents
11.3.6. Others
11.4. Market Value Forecast By Product Type, 2017-2031
11.4.1. Prescription Drugs
11.4.2. OTC Drugs
11.5. Market Value Forecast By Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Online Pharmacies
11.5.3. Independent Pharmacies & Drug Stores
11.6. Market Value Forecast By Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Therapeutic Class
11.7.3. By Product Type
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Ophthalmic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Disease Indication, 2017-2031
12.2.1. Dry Eye
12.2.2. Glaucoma
12.2.3. Infection/Inflammation
12.2.4. Retinal Disorders
12.2.4.1. Wet AMD
12.2.4.2. Dry AMD
12.2.4.3. Diabetic Retinopathy
12.2.4.4. Others
12.2.5. Allergy
12.2.6. Uveitis
12.2.7. Others
12.3. Market Value Forecast By Therapeutic Class, 2017-2031
12.3.1. Anti-inflammatory Drugs
12.3.1.1. NSAIDs
12.3.1.2. Steroids
12.3.2. Anti-infective Drugs
12.3.2.1. Anti-fungal Drugs
12.3.2.2. Anti-bacterial Drugs
12.3.2.3. Others
12.3.3. Anti-glaucoma Drugs
12.3.3.1. Alpha Agonist
12.3.3.2. Beta Blockers
12.3.3.3. Prostaglandin Analogs
12.3.3.4. Combined Medication
12.3.3.5. Others
12.3.4. Anti-allergy Drugs
12.3.5. Anti-VEGF Agents
12.3.6. Others
12.4. Market Value Forecast By Product Type, 2017-2031
12.4.1. Prescription Drugs
12.4.2. OTC Drugs
12.5. Market Value Forecast By Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Online Pharmacies
12.5.3. Independent Pharmacies & Drug Stores
12.6. Market Value Forecast By Country, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Therapeutic Class
12.7.3. By Product Type
12.7.4. By Distribution Channel
12.7.5. By Country
13. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Disease Indication, 2017-2031
13.2.1. Dry Eye
13.2.2. Glaucoma
13.2.3. Infection/Inflammation
13.2.4. Retinal Disorders
13.2.4.1. Wet AMD
13.2.4.2. Dry AMD
13.2.4.3. Diabetic Retinopathy
13.2.4.4. Others
13.2.5. Allergy
13.2.6. Uveitis
13.2.7. Others
13.3. Market Value Forecast By Therapeutic Class, 2017-2031
13.3.1. Anti-inflammatory Drugs
13.3.1.1. NSAIDs
13.3.1.2. Steroids
13.3.2. Anti-infective Drugs
13.3.2.1. Anti-fungal Drugs
13.3.2.2. Anti-bacterial Drugs
13.3.2.3. Others
13.3.3. Anti-glaucoma Drugs
13.3.3.1. Alpha Agonist
13.3.3.2. Beta Blockers
13.3.3.3. Prostaglandin Analogs
13.3.3.4. Combined Medication
13.3.3.5. Others
13.3.4. Anti-allergy Drugs
13.3.5. Anti-VEGF Agents
13.3.6. Others
13.4. Market Value Forecast By Product Type, 2017-2031
13.4.1. Prescription Drugs
13.4.2. OTC Drugs
13.5. Market Value Forecast By Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Online Pharmacies
13.5.3. Independent Pharmacies & Drug Stores
13.6. Market Value Forecast By Country, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Therapeutic Class
13.7.3. By Product Type
13.7.4. By Distribution Channel
13.7.5. By Country
14. Latin America Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Disease Indication, 2017-2031
14.2.1. Dry Eye
14.2.2. Glaucoma
14.2.3. Infection/Inflammation
14.2.4. Retinal Disorders
14.2.4.1. Wet AMD
14.2.4.2. Dry AMD
14.2.4.3. Diabetic Retinopathy
14.2.4.4. Others
14.2.5. Allergy
14.2.6. Uveitis
14.2.7. Others
14.3. Market Value Forecast By Therapeutic Class, 2017-2031
14.3.1. Anti-inflammatory Drugs
14.3.1.1. NSAIDs
14.3.1.2. Steroids
14.3.2. Anti-infective Drugs
14.3.2.1. Anti-fungal Drugs
14.3.2.2. Anti-bacterial Drugs
14.3.2.3. Others
14.3.3. Anti-glaucoma Drugs
14.3.3.1. Alpha Agonist
14.3.3.2. Beta Blockers
14.3.3.3. Prostaglandin Analogs
14.3.3.4. Combined Medication
14.3.3.5. Others
14.3.4. Anti-allergy Drugs
14.3.5. Anti-VEGF Agents
14.3.6. Others
14.4. Market Value Forecast By Product Type, 2017-2031
14.4.1. Prescription Drugs
14.4.2. OTC Drugs
14.5. Market Value Forecast By Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Online Pharmacies
14.5.3. Independent Pharmacies & Drug Stores
14.6. Market Value Forecast By Country, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Therapeutic Class
14.7.3. By Product Type
14.7.4. By Distribution Channel
14.7.5. By Country
15. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Disease Indication, 2017-2031
15.2.1. Dry Eye
15.2.2. Glaucoma
15.2.3. Infection/Inflammation
15.2.4. Retinal Disorders
15.2.4.1. Wet AMD
15.2.4.2. Dry AMD
15.2.4.3. Diabetic Retinopathy
15.2.4.4. Others
15.2.5. Allergy
15.2.6. Uveitis
15.2.7. Others
15.3. Market Value Forecast By Therapeutic Class, 2017-2031
15.3.1. Anti-inflammatory Drugs
15.3.1.1. NSAIDs
15.3.1.2. Steroids
15.3.2. Anti-infective Drugs
15.3.2.1. Anti-fungal Drugs
15.3.2.2. Anti-bacterial Drugs
15.3.2.3. Others
15.3.3. Anti-glaucoma Drugs
15.3.3.1. Alpha Agonist
15.3.3.2. Beta Blockers
15.3.3.3. Prostaglandin Analogs
15.3.3.4. Combined Medication
15.3.3.5. Others
15.3.4. Anti-allergy Drugs
15.3.5. Anti-VEGF Agents
15.3.6. Others
15.4. Market Value Forecast By Product Type, 2017-2031
15.4.1. Prescription Drugs
15.4.2. OTC Drugs
15.5. Market Value Forecast By Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Online Pharmacies
15.5.3. Independent Pharmacies & Drug Stores
15.6. Market Value Forecast By Country, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Disease Indication
15.7.2. By Therapeutic Class
15.7.3. By Product Type
15.7.4. By Distribution Channel
15.7.5. By Country
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Aerie Pharmaceuticals, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Allergan plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Valeant Pharmaceuticals International, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bayer AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Novartis AG.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Pfizer Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Regeneron Pharmaceuticals, Inc
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Santen Pharmaceutical Co., Ltd
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
List of Tables
Table 01: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2017-2031
Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017-2031
Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017-2031
Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017-2031
Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 10: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 12: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2017-2031
Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017-2031
Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017-2031
Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017-2031
Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channels, 2017-2031
Table 19: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
Table 20: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 21: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2017-2031
Table 22: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 23: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2017-2031
Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2017-2031
Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2017-2031
Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 28: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 29: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 30: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2017-2031
Table 31: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 32: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017-2031
Table 33: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017-2031
Table 34: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017-2031
Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 37: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 38: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 39: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2017-2031
Table 40: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 41: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017-2031
Table 42: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017-2031
Table 43: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017-2031
Table 44: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 45: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 46: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
Table 47: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
Table 48: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication - Retinal Disorders, 2017-2031
Table 49: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 50: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017-2031
Table 51: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017-2031
Table 52: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017-2031
Table 53: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 54: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2031
Figure 03: Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2017-2031
Figure 04: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2017-2031
Figure 05: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2017-2031
Figure 06: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2017-2031
Figure 07: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2017-2031
Figure 08: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2017-2031
Figure 09: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2017-2031
Figure 10: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2017-2031
Figure 11: Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 12: Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017-2031
Figure 13: Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 14: Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 15: Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 16: Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 17: Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 18: Global Ophthalmic Drugs Market, by Others, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017-2031
Figure 19: Global Ophthalmic Drugs Market Value Share, by Product Type, for 2017-2031
Figure 20: Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 21: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2017-2031
Figure 22: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2017-2031
Figure 23: Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017-2031
Figure 24: Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2031
Figure 25: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2017-2031
Figure 26: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2017-2031
Figure 27: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2017-2031
Figure 28: Global Ophthalmic Drugs Market Value Share, by Region, for 2017-2031
Figure 29: Global Ophthalmic Drugs Market Attractiveness, by Region, 2017-2031
Figure 30: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 31: North America Ophthalmic Drugs Market Attractiveness, by Country, 2017-2031
Figure 32: North America Ophthalmic Drugs Market Value Share, by Country, 2017-2031
Figure 33: North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2017-2031
Figure 34: North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017-2031
Figure 35: North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017-2031
Figure 36: North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 37: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017-2031
Figure 38: North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 39: North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2017-2031
Figure 40: North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels, 2017-2031
Figure 41: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 42: Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017-2031
Figure 43: Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017-2031
Figure 44: Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
Figure 45: Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2017-2031
Figure 46: Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017-2031
Figure 47: Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 48: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017-2031
Figure 49: Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 50: Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017-2031
Figure 51: Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2031
Figure 52: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 53: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017-2031
Figure 54: Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2017-2031
Figure 55: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2031
Figure 56: Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2017-2031
Figure 57: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 58: Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2017-2031
Figure 59: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2017-2031
Figure 60: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 61: Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017-2031
Figure 62: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2031
Figure 63: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 64: Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017-2031
Figure 65: Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2017-2031
Figure 66: Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2031
Figure 67: Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017-2031
Figure 68: Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 69: Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017-2031
Figure 70: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017-2031
Figure 71: Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 72: Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017-2031
Figure 73: Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2031
Figure 74: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 75: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017-2031
Figure 76: Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017-2031
Figure 77: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2031
Figure 78: Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2017-2031
Figure 79: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2031
Figure 80: Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017-2031
Figure 81: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017-2031
Figure 82: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2031
Figure 83: Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017-2031
Figure 84: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2031
Figure 85: Global Ophthalmic Drugs Market Share, by Company, 2016
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security